Which is more enduring--FAME or COURAGE?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

1. Fractional flow reserve-guided percutaneous coronary intervention vs. medical therapy for patients with stable coronary lesions: meta-analysis of individual patient data.European heart journal · 2019
   Pooled it
2. Functional Versus Anatomic Imaging of CAD: Lessons Learned from Recent Clinical Trials.Current cardiology reports · 2016
   Pooled it
3. Accuracy of Computed Tomographic Angiography and Single-Photon Emission Computed Tomography-Acquired Myocardial Perfusion Imaging for the Diagnosis of Coronary Artery Disease.Circulation. Cardiovascular imaging · 2015
   Trial
4. Impact of myocardial ischemia on myocardial revascularization in stable ischemic heart disease. Lessons from the COURAGE and FAME 2 trials.Herz · 2013
   Trial
5. Coronary flow capacity and survival prediction after revascularization: physiological basis and clinical implications.European heart journal · 2024
   Article
6. Coronary "Microvascular Dysfunction": Evolving Understanding of Pathophysiology, Clinical Implications, and Potential Therapeutics.International journal of molecular sciences · 2023
   Review
7. Unstable Angina as a Component of Primary Composite Endpoints in Clinical Cardiovascular Trials: Pros and Cons.Cardiology · 2022
   Review
8. Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied.Frontiers in cardiovascular medicine · 2018
   Review
9. Noninvasive Cardiac Imaging in Patients with Known and Suspected Coronary Artery Disease: What is in it for the Interventional Cardiologist?Current cardiology reports · 2016
   Review
10. Comprehensive assessment of coronary fractional flow reserve.Archives of medical science : AMS · 2015
    Article
11. Fractional flow reserve-guided percutaneous coronary intervention is not a valid concept.Circulation · 2014
    Article
12. Fractional flow reserve-guided percutaneous coronary intervention: does coronary pressure never lie?Current treatment options in cardiovascular medicine · 2014
    Article
13. [Diagnostics and therapy of chronic myocardial ischemia: the when and how of diagnostic work-up and therapy].Herz · 2013
    Article
14. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Vascular health and risk management · 2013
    Review
15. Nuclear stress perfusion imaging versus computed tomography coronary angiography for identifying patients with obstructive coronary artery disease as defined by conventional angiography: insights from the CorE-64 multicenter study.Heart international
    Article

Corrections and comments

• Comment on
  Optimal medical therapy with or without PCI for stable coronary disease.2007
• Comment on
  Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease.2012

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as